Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
Authors: Sung Eun Lee
Soo Young Choi
Soo Hyun Kim
Saengsuree Jootar
Hyeoung Joon Kim
Sang Kyun Sohn
Joon Seong Park
Sung Hyun Kim
Dae Young Zang
Suk Joong Oh
Dong Wook Kim
Ajou University, School of Medicine
Kyungpook National University Hospital
Chonnam National University, College of Medicine
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Dong-A University, College of Medicine
Samsung Group
Hallym University, College of Medicine
The Catholic University of Korea
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Jul-2018
Citation: Leukemia Research. Vol.70, (2018), 100-105
Abstract: © 2018 Elsevier Ltd The aim of this study was to investigate the efficacy of nilotinib (NIL) versus high-dose imatinib (IM) versus sustained standard-dose IM for patients with chronic myeloid leukemia (CML) with suboptimal molecular response to first-line IM therapy. Patients with CML who achieved complete cytogenetic response (CCyR) but not major molecular response (MMR) after 18–24 months on first-line IM therapy were enrolled and divided into three treatment cohorts: NIL 800 mg/day (Cohort 1, n = 28) and IM 800 mg/day (Cohort 2, n = 28) in the RE-NICE study, and sustained IM 400 mg/day (Cohort 3, n = 52) in clinical practice. The primary efficacy variable of cumulative rate of MMR by 12 months was not different among the three cohorts. However, the cumulative incidence of MMR by 36 months was significantly higher in Cohort 1 than Cohort 3 (83.1% vs. 57.1%, P = 0.021), but there were no significant differences in Cohort 1 vs. 2 (P = 0.195) and Cohort 2 vs. 3 (P = 0.297). Different profile for adverse events was observed between NIL and high-dose IM therapy. In conclusion, our data suggested that switching to NIL may provide more effective long-term response than sustaining standard-dose IM for patients with suboptimal molecular response to first-line IM.
ISSN: 18735835
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.